Navigation Links
Genasense(R) Can be Administered by Brief High-Dose IV Infusion
Date:10/23/2007

New Trial Reaffirms Primacy and Safety of 'First Generation' Antisense

BERKELEY HEIGHTS, N.J., Oct. 23 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced the presentation of new data showing that Genasense(R) (oblimersen sodium) Injection, its lead anticancer compound, can be safely administered in high doses by a brief intravenous (IV) infusion. The new data were presented by Dr. Anthony Tolcher, Director of Clinical Research, South Texas Accelerated Research Therapeutics (START), and Clinical Professor of Medicine, University of Texas Health Science Center, San Antonio, TX. The presentation was made during the "Molecular Targets and Therapeutics" meeting in San Francisco, CA, which was jointly sponsored by the U.S. National Cancer Institute (NCI), the American Association for Cancer Research (AACR), and the European Organization for the Research and Treatment of Cancer (EORTC).

High-dose IV injections of so-called "first generation" antisense compounds, known as phosphorothioates, have been associated with severe toxicity in monkey studies. As a consequence, clinical use of these drugs has sought to avoid high plasma concentrations by using continuous IV administration of low doses. During its Phase 3 clinical trials, Genta developed a safety database involving patients who tolerated accidental overdoses, which suggested that the animal experience might not be clinically predictive. Additional preclinical data have also suggested that intermittent high-dose injections are associated with equal or superior antitumor efficacy. The Company has now developed clinical data that establishes Genasense can be safely administered by both subcutaneous injection as well as brief IV infusion.

<
'/>"/>
SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
2. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
3. Low-Dose Steroid Combined With Lenalidomide Prolongs Survival Compared With High-Dose Steroid for Multiple Myeloma Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 ... specialty biotechnology company focused on developing aerosolized KL4 ... live teleconference and webcast at 8:30 a.m. Eastern Time ... management will discuss the 2015 second quarter financial ... company will issue a press release announcing the ...
(Date:8/3/2015)... 3, 2015 Your doctor has recommended surgery ... for the best possible outcome. Your orthopaedic foot and ... and now there,s a three-part online series ... the American Orthopaedic Foot & Ankle Society (AOFAS) ... avoid complications and heal as quickly as possible. ...
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
Breaking Medicine Technology:Discovery Labs to Hold Conference Call on Tuesday August 11, 2015 to Discuss Second Quarter 2015 Financial Results and Other Business Updates 2Patient Guide: How to Prepare for Surgery 2Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... 1, 2011 PTC Therapeutics, Inc. (PTC) today announced ... of ataluren, an investigational new drug, in adults with ... Respiratory Journal . The published three-month data showed that ... chloride channel activity, CF-related cough and positive trends in ...
... READING, England and BEDMINSTER, N.J., June 30, 2011 ... Inc., today announced that the U.S. Food and Drug ... the management of breakthrough pain in cancer patients 18 ... and who are tolerant to opioid therapy for their ...
Cached Medicine Technology:Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 2Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 3Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 4Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 5Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 2FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 3FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 4FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 5FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 6FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 7FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients 8
(Date:8/4/2015)... ... August 04, 2015 , ... Armadale Capital ... announced the closing of a $118 million FHA-insured loan modification refinancing for Johnston ... Smithfield and Clayton, North Carolina. JHSC is a joint venture of Johnston ...
(Date:8/4/2015)... ... August 04, 2015 , ... Oriental Trading Company, ... toys, novelties, and school supplies, has developed engaging and affordable teacher supplies based ... includes student rewards, classroom decorations, crafts and educational resources featuring Carle’s vibrant ...
(Date:8/4/2015)... ... 2015 , ... It is National Psoriasis Awareness Month, and we are reminded ... as dry, itching, burning or soreness of skin that may crack or bleed. , ... what’s right for them. Then, what is effective may stop working, so they have ...
(Date:8/4/2015)... ... ... The goal of looking younger – with a fresher, more rested appearance ... ideal is not. But minimally invasive procedures such as dermal fillers, tighteners or laser ... time, according to Valerie Goldburt, MD, PhD , of Advanced Dermatology P.C. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Nathan’s Famous was recently featured ... medium, and large businesses making an impact in their industry. Andrew Tropeano, the host ... the famous hot dog maker now offers a 50% Reduced Fat All-Beef Frank ...
Breaking Medicine News(10 mins):Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 2Health News:Armadale Capital Inc. Refinances $118 Million for Johnston Health Services Corporation 3Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 2Health News:Oriental Trading Company Brings The World of Eric Carle Characters to Educators Through Classroom Supplies 3Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 2Health News:USA Medical Card Offers a Solution During National Psoriasis Awareness Month 3Health News:Considering fillers, tighteners or laser resurfacing? 2Health News:Considering fillers, tighteners or laser resurfacing? 3Health News:Considering fillers, tighteners or laser resurfacing? 4Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 2Health News:Celebrate Summer with Nathan’s Famous Original Selfie Sweepstakes 3
... and ,Samantha Who?, to be Honored at Donate Life Film ... June 5 On June 13, Donate Life Hollywood will ... "Samantha Who?" with its first annual Inspire Award. This honor, ... be presented at the culmination of the daylong Donate Life ...
... evident with seniors, researchers say , FRIDAY, June 5 (HealthDay ... new generation of video games that require users to get ... bit more fit. , New research suggests that several exercise-based ... equal to that of light jogging. , And seniors in ...
... Joseph F. Finn, Jr., C.P.A. ("Finn") announced today ... Cancer Research Ltd., Brussels Branch. The statement is quoted ... product candidate, GCS-100, is a carbohydrate molecule which inhibits the ... a broad range of human cancers. Prospect reported that ...
... show, , FRIDAY, June 5 (HealthDay News) -- One reason ... not that interesting. But what if you could dance your ... suggest that you just might be able to do that. ... meeting in Seattle, one study found that salsa dancing could ...
... region are ready to prescribe and dispense medications electronically , ... of Spain and IBM (NYSE: IBM ) have ... where health centres and pharmacies are now computerised and able ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ...
... are experiencing onerous fatigue four months after the infarction. The ... infarction as a sign of chronic illness, those who experience ... that the illness has a large impact on their life. ... Sahlgrenska Academy, University of Gothenburg, Sweden. Just over 200 ...
Cached Medicine News:Health News:ABC-TV Gets It Right According to Organ Donation Community 2Health News:Interactive Video Games Offer Exercise Benefits 2Health News:Interactive Video Games Offer Exercise Benefits 3Health News:Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule 2Health News:Finding Fitness on the Dance Floor 2Health News:Finding Fitness on the Dance Floor 3Health News:Spain's Regional Extremadura Government Launches Electronic Prescription System With IBM 2Health News:Fatigue common after myocardial infarction 2